Global Genitourinary Drugs Market is Expected to Register a Healthy CAGR in the Forecast Period of 2019 to 2026

According to Data Bridge Market Research new Market report, global genitourinary drugs market will account to reach an estimated USD 31.18 billion in 2018 growing at a CAGR of 3.4% during the forecast period of 2019 to 2026.

Access Full Report at https://databridgemarketresearch.com/reports/global-genitourinary-drugs-market/

Global Genitourinary Drugs Market

To treat cancer in bladder, urethra, ureters and kidney, usually genitourinary drugs are used. Impotence agents, tocolytic agent, urinary pH modifiers, uterotonic agents, urinary antispasmodics and miscellaneous genitourinary tract agents are some of the genitourinary tract agents. Sometime this genitourinary drug cause’s infection likes glomerulonephritis, prostate cancer, polycystic kidney disease etc. that can be solved by various steroids and immunosuppressants.

Segmentation: Global Genitourinary Drugs Market

Global genitourinary drugs market is segmented on the basis of disease, products and geography.

By Disease (Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Kidney/Renal Cancer, Genitourinary Cancer), Products (Sex Hormones, Urologicals, Genitourinary Anti-Infectives, Gynaecologicals), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Recent Developments

  • In September 2018, TherapeuticsMD, Inc. announced the commercial availability of the Imvexxy 4 mcg in U.S. for the treatment of dyspareunia.
  • In May 2016, Genentech, Inc. announced the FDA approval of its product Atezolizumab which is an anti–PD-L1 cancer immunotherapy and used for the patients with the urothelial carcinoma.

Key Market Competitors: Global Genitourinary Drugs Market

Few of the major market competitors currently working in the genitourinary drugs market are Pfizer, Astellas, Betanis, Botox, Glaxo Wellcome Plc, Anturol, GlaxoSmithKline, Eli Lilly, Bayer AG, Merck KGaA, Abbott Laboratories, Merck & Co., Agouron Pharmaceuticals Inc., Chiron Inc., Bristol-Myers Squibb Co., Connaught Laboratories Inc., Genentech Inc., Hoffman-La Roche Inc., Immunex Corp., Isis Pharmaceuticals, Pharmacia & John Inc., Quadra Logic Technologies Inc., Photofrin, Rhone Poulenc Rorer Inc., Schering Plough Corp., and Leucomax.

Browse Related Reports:

Global Drug Discovery Outsourcing Market By Workflow (Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development, Other Associated Workflow), Therapeutic Area (Respiratory System, Pain and Anaesthesia, Oncology, Ophthalmology, Haematology, Cardiovascular, Endocrine, Gastrointestinal, Immunomodulation, Anti-Infective,  Central Nervous System, Dermatology, Genitourinary System), Drug Type (Small Molecules, Large Molecules), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)– Industry Trends and Forecast to 2026

https://databridgemarketresearch.com/reports/global-drug-discovery-outsourcing-market/

Global Therapeutic Drug Monitoring Market, By product (consumables and devices), By technology (immunoassays, proteomic technologies), By class of drugs (antiepileptic, antiarrhythmic, immunosuppresants and others), By Therapeutic areas (alimentary tract, hematological disease, and others), By By End Users (Hospital Labs, Labs and others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)– Industry Trends and Forecast to 2025

https://databridgemarketresearch.com/reports/global-therapeutic-drug-monitoring-market/